ORMP

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a clinical-stage biotechnology company founded in 2002 and headquartered in New York. The company was originally incorporated as Integrated Security Technologies, Inc. before changing its name to Oramed Pharmaceuticals in April 2006 and going public in May 2007. Oramed specializes in developing oral drug delivery systems for medications that traditionally require injection, with a primary focus on creating the world's first commercially viable oral insulin capsule for diabetes treatment.